Updated on 8 October 2012
"It is becoming a real concern that early research is less attractive to investors and the next few years will continue to be difficult. However, as the large pharma companies know, there is a need to keep the overall pipeline funded in order to develop new drugs and therapies," she added.
(Dr Haile will be speaking about Recent Developments in US & Australian Patent Law & their Impact on the Biotechnology Industry at AusBiotech to be held in Melbourne from October 30- November 02, 2012)
Get direct access to more such reports. Subscribe to BioSpectrum Bureau 
Survey Box
Subscribe to BioSpectrum Asia digital mag at an attractive price of US $49.99 a year
(Includes all 24 regular & special issues @ fortnightly frequency)
Send this article by email
Australia
China
India
Japan
Korea
Malaysia
New Zealand 
Singapore
Taiwan
Thailand
1Comment
Comment 1 - 1 of 1
Rekha 9 October 2012 at 04 PM
Intellectual property is increasingly becoming an interesting space to watch in the bioscience industry. With drug patents under threat in countries like India, there is indeed much happening on this front. Clearer and more uniform laws are welcome
Reply